We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
OWC Pharmaceuticals Research Corporation (CE) | USOTC:OWCP | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.000001 | 0.00 | 01:00:00 |
OMB APPROVAL | ||
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 |
OMB Number: 3235-0167 Expires: November 30, 2010 Estimated average burden hours per response . . . . . . . . . . 1.50 |
FORM 15
CERTIFICATION
AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION
12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE
REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 000-54856
OWC PHARMACEUTICAL RESEARCH CORP. |
(Exact name of registrant as specified in its charter) |
2 Ben Gurion St., Ramat Gan Israel 5257334 +972-72-260-8004 |
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices) |
Common Stock, par value $0.0001 |
(Title of each class of securities covered by this Form) |
None |
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains) |
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
Rule 12g-4(a)(1) | [X] | |
Rule 12g-4(a)(2) | [ ] | |
Rule 12h-3(b)(1)(i) | [X] | |
Rule 12h-3(b)(1)(ii) | [ ] | |
Rule 15d-6 Rule 15d-22(b) |
[ ] [ ] |
Approximate number of holders of record as of the certification or notice date: 224
Pursuant
to the requirements of the Securities Exchange Act of 1934, OWC Pharmaceutical Research Corp. has caused this certification/notice
to be signed on its behalf by the undersigned duly authorized person.
Date: | March 31, 2020 | By: | ||
Zvi Riterband, Chief Executive Officer |
Instruction: This form is required by Rules 12g-4, 12h-3, 15d-6 and Rule 15d-22 of the General Rules and Regulations under the Securities Exchange Act of 1934. The registrant shall file with the Commission three copies of Form 15, one of which shall be manually signed. It may be signed by an officer of the registrant, by counsel or by any other duly authorized person. The name and title of the person signing the form shall be typed or printed under the signature.
SEC2069(02-08) | Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OBM control number. |
1 Year OWC Pharmaceuticals Rese... (CE) Chart |
1 Month OWC Pharmaceuticals Rese... (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions